AnalystBook Research · Company Intelligence

Agape ATP Corp

ATPCNasdaq

Built from Agape ATP Corp's own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

Agape ATP revenue rose 15.2% to $1.5M and net loss narrowed, while equity rose sharply and screens were safe.

The read at a glance✓ Audited against SEC data
  • Business mixHealth, wellness, and green energy productsNote
  • RevenueRevenue rose 15.2%OK
  • LossesNet loss narrowed to $2.3MOK
  • CashCash from ops -$2.4MWatch
  • Balance sheetEquity rose to $22.5MOK
  • Insiders0 buys / 0 sellsNote
  • AccountingAltman-Z safe; EQ safeOK

Business

Agape ATP sells health and wellness products and advisory services in Malaysia, with tagged rows for skin care and health and wellness plus green energy.

Where the revenue comes from

Fiscal 2025, as Agape ATP Corp reports it. History and quarterly detail are in the app.

  • Skin Care Health And Wellness$1.4M
  • Green Energy$140K

Leadership changes

From Agape ATP Corp's own filings, the day they're filed.

  • Wilfrendo Fernando Cortizo · director · appointmenteff. 2023-11-21
  • John Hing Vong · Chairman · departure
  • Technical Advisor · Chief Executive Officer · appointment

Latest filings

  • 10-Q · Quarterly report2026-08-14
  • 10-Q · Quarterly report2026-05-15
  • 10-K · Annual report2026-04-13
  • 8-K · Company announcement2026-03-12
  • 8-K · Company announcement2026-03-10
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • Main tension🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about Agape ATP Corp, every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.